GLP-1 Agents May Reduce Psoriasis Severity
National Psoriasis Foundation review highlights limited evidence and potential metabolic links.
By
Andrea Surnit
May 5, 2026
Clinical Scorecard: GLP-1 Agents May Reduce Psoriasis Severity
At a Glance
Category Detail
Condition Psoriasis Key Mechanisms Metabolic and immune effects, including reductions in inflammatory markers and changes in immune cell populations. Target Population Patients with psoriasis, particularly those with obesity or type 2 diabetes. Care Setting Dermatology and metabolic health clinics.
Key Highlights
GLP-1 RAs may reduce PASI scores by 40% to 80% in selected patients. Semaglutide and liraglutide showed significant PASI reductions in small trials. Adverse effects are primarily gastrointestinal; rare risks include pancreatitis. GLP-1 RAs can be coadministered with other psoriasis therapies. Current evidence is limited by small sample sizes and short follow-up durations. Guideline-Based Recommendations
Diagnosis
Consider metabolic comorbidities in psoriasis patients. Management
GLP-1 RAs may be considered as adjunct therapy in selected patients. Monitoring & Follow-up
Monitor for gastrointestinal adverse effects and potential rare risks. Risks
Potential for pancreatitis, gallbladder disease, and injection-site reactions. Patient & Prescribing Data
Patients with psoriasis, particularly those with obesity or type 2 diabetes.
Use of GLP-1 RAs in psoriasis is off-label and primarily driven by cardiometabolic indications.
Clinical Best Practices
Evaluate metabolic status in psoriasis patients before considering GLP-1 RA therapy. Monitor PASI scores and metabolic parameters during treatment. Educate patients on potential gastrointestinal side effects. Related Resources & Content
